REACT assesses clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia following subarachnoid hemorrhage Japanese registration program with ...
Idorsia Ltd (IDIA.SW) today announced that the first patient has been included into REACT, a Phase 3 registration study to investigate the efficacy and safety of clazosentan for the prevention of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback